Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

Opdivo plus Yervoy significantly improved PFS in MSI-H/dMMR metastatic CRC compared to Opdivo alone, with sustained separation of PFS curves. The combination therapy showed higher ORR and complete ...

Among older adult patients with classical Hodgkin lymphoma (cHL), frontline treatment with the combination of the immunotherapy Opdivo (nivolumab) plus the chemotherapy drugs doxorubicin, vinblastine ...

Bristol Myers (BMY) Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo plus Yervoy for the first-line ...

How Do Opdivo and Opdivo Qvantig Work for Lung Cancer? Some cancer cells have what are called checkpoint proteins on their cell surface. The immune cells in our bodies also have proteins on their ...

Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

(Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 billion, according to LSEG data. It forecast 2025 earnings in the ...